Track the 선바이오 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 선바이오 has recorded 10 reports. Market capitalisation: €78.7bn. The latest transaction was disclosed on 23 April 2026 (Purchase). Among the most active insiders: 노광. The full history is accessible without an account.
10
Insider Decl.
n/a
Thresholds
€32,402
10 ops.
Buy Volume
n/a
n/a
Sell Volume
31Σ signal
Buys €32,402n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,795 of 29,063 companies
56.7
score / 100
Value
44
Quality
70
FCF yld0.8%
Earn yld3.8%
EV/EBITDA17.2x
ROE35%
Gross mgn61%
Net mgn20%
Debt/EBITDA4.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Sunbio operates in the health and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative solutions in the healthcare field.